MedBot Poised for Growth with Surgical Robot Penetration Across Five Specialties

Shanghai MicroPort MedBot (HKG: 2252), the surgical robotics division of medical device developer MicroPort (HKG: 0853), specializes in designing, developing, and commercializing advanced surgical robots to aid surgeons in complex procedures across five major specialties: laparoscopic, orthopedic, panvascular, natural orifice, and percutaneous surgeries.

MedBot leads globally by covering all five major surgical specialties. Its flagship laparoscopic surgery segment, featuring the Toumai laparoscopic surgical robot and DFVision 3D electronic laparoscopic device, launched in 2022, is the largest revenue generator, expected to generate CNY136 million in 2024. The company has expanded its portfolio with the SkyWalker orthopedic surgical robot introduced in 2023, which is projected to generate CNY71 million this year. SkyWalker is currently approved for use in China, the U.S., the EU, Brazil, and Australia. MedBot has also newly launched devices for panvascular and percutaneous surgeries, which is expected to bolster the company’s revenues further. According to Visible Alpha consensus, MedBot is poised for continued growth momentum, with total revenue forecasted to grow at a CAGR of 150% between 2024 and 2026, reaching CNY1.4 billion by 2026.